Appeal No. 2003-0835 Page 2
Application No. 09/419,371
and said repressor is a CREB/CREM/ATF-1 subfamily member
associated with blocking of long term memory.
15. A method for assessing the effect of a drug on long term
memory formation comprising:
a) administering said drug to an animal; and
b) determining the functional level of activator or repressor in
said animal relative to the functional level of activator or repressor,
respectively, in a control animal to which said drug has not been
administered, wherein said activator is a CREB/CREM/ATF-1
subfamily member associated with potentiation of long tem memory
and said repressor is a CREB/CREM/ATF-1 subfamily member
associated with blocking of long term memory.
33. A method for assessing the effect of a drug on long term
memory formation comprising:
a) administering said drug to an animal; and
b) determining the functional level of a homodimer of a
repressor relative to the functional level of said homodimer present
in a control animal to which said drug has not been administered,
wherein said repressor is an antagonist of a CREB/CREM/ATF-1
subfamily member and is associated with blocking of long term
memory.
Claims 9-20 and 39-50 stand rejected under 35 U.S.C. § 112, second
paragraph. In addition, claims 9-20 and 39-50 stand rejected under 35 U.S.C. §
112, first paragraph, for lack of adequate written description. Finally, claims 9-20
and 39-50 stand rejected under 35 U.S.C. § 112, first paragraph, on the basis of
lack of enablement. After careful review of the record and consideration of the
issues before us, we reverse all of the rejections of record.
BACKGROUND
According to the specification:
Page: Previous 1 2 3 4 5 6 7 8 9 10 11 12 Next
Last modified: November 3, 2007